TY - JOUR
T1 - Unilateral motor progression in MS
T2 - Association with a critical corticospinal tract lesion
AU - Sechi, Elia
AU - Keegan, B. Mark
AU - Kaufmann, Timothy J.
AU - Kantarci, Orhun H.
AU - Weinshenker, Brian G.
AU - Flanagan, Eoin P.
N1 - Funding Information:
E. Sechi reports no disclosures relevant to the manuscript. B. Keegan has research funded by Biogen and receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases. He is an Editorial Board member of Multiple Sclerosis and Related Disorders. T. Kaufmann reports no disclosures relevant to the manuscript. O. Kantarci received speaker honoraria (paid to Mayo Clinic) from Novartis and Biogen; performed a grant review for the National Multiple Sclerosis Society; and received research support from Biogen, the Multiple Sclerosis Society, the Mayo Foundation, and the Hilton Foundation. B. Weinshenker receives royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr. Volkmann und Kollegen GbR for a patent of neuromyelitis optica (NMO)–immunoglobulin G as a diagnostic test for NMO and related disorders. He serves as a member of an adjudication committee for clinical trials in NMO being conducted by Viela Bio Inc. and Alexion Pharmaceutical Co. He is a consultant for Caladrius Biosciences, Brainstorm Therapeutics, Roivant Sciences, and Chugai Pharma regarding potential clinical trials for NMO. E. Flanagan receives research support as a site principal investigator in a randomized placebo-controlled clinical trial of inebilizumab (a CD19 inhibitor) in NMO spectrum disorders funded by MedImmune/Viela Bio. Go to Neurology.org/N for full disclosures.
Funding Information:
This study was supported by a research fellowship funded by the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology.
Publisher Copyright:
© American Academy of Neurology.
PY - 2019/8/13
Y1 - 2019/8/13
N2 - ObjectiveProgressive motor impairment anatomically attributable to a single critical demyelinating lesion on eloquent corticospinal tract locations occurs in progressive solitary sclerosis and in some patients with multiple sclerosis (MS) with highly restricted CNS lesion burden (2-5 lesions). We determined whether a similar critical lesion is found in patients with MS with unilateral motor progression and unlimited lesion burden.MethodsIn this observational study, we retrospectively identified Mayo Clinic patients (January 1, 1996-December 31, 2017) with an MS diagnosis (2017 McDonald criteria), ≥1 year of exclusively unilateral motor progression, and >5 demyelinating lesions on MRI. A blinded neuroradiologist identified a single critical lesion (last available MRI) based on prominent size, atrophy, and eloquent corticospinal tract location (spinal cord lateral columns, medullary pyramids, cerebral peduncles, internal capsules). We then determined whether the motor impairment was anatomically attributable to the identified lesion.ResultsThirty-eight patients with MS were included: 20 (53%) with primary progressive MS and 18 (47%) with secondary progressive MS. Median age at progression onset was 54 (range 39-73) years. Median Expanded Disability Status Scale score was 5 (range 2.5-7.5) at the last follow-up (median 132.5 months from symptom onset, range 23-390 months). A single critical lesion was identified in 25 of 38 cases (66%): 19 in the cervical cord and 6 in the thoracic cord. In the remaining patients, >1 potential critical lesions were present. The overall probability to detect demyelinating lesions was higher along the corticospinal tract where the motor deficit localized (38 of 38 [100%]) than on the contralateral side (15 of 38 [39%]) (p < 0.0001).ConclusionsIn patients with MS with unilateral motor progression, the motor deficit may be attributable to a single critical corticospinal tract lesion.
AB - ObjectiveProgressive motor impairment anatomically attributable to a single critical demyelinating lesion on eloquent corticospinal tract locations occurs in progressive solitary sclerosis and in some patients with multiple sclerosis (MS) with highly restricted CNS lesion burden (2-5 lesions). We determined whether a similar critical lesion is found in patients with MS with unilateral motor progression and unlimited lesion burden.MethodsIn this observational study, we retrospectively identified Mayo Clinic patients (January 1, 1996-December 31, 2017) with an MS diagnosis (2017 McDonald criteria), ≥1 year of exclusively unilateral motor progression, and >5 demyelinating lesions on MRI. A blinded neuroradiologist identified a single critical lesion (last available MRI) based on prominent size, atrophy, and eloquent corticospinal tract location (spinal cord lateral columns, medullary pyramids, cerebral peduncles, internal capsules). We then determined whether the motor impairment was anatomically attributable to the identified lesion.ResultsThirty-eight patients with MS were included: 20 (53%) with primary progressive MS and 18 (47%) with secondary progressive MS. Median age at progression onset was 54 (range 39-73) years. Median Expanded Disability Status Scale score was 5 (range 2.5-7.5) at the last follow-up (median 132.5 months from symptom onset, range 23-390 months). A single critical lesion was identified in 25 of 38 cases (66%): 19 in the cervical cord and 6 in the thoracic cord. In the remaining patients, >1 potential critical lesions were present. The overall probability to detect demyelinating lesions was higher along the corticospinal tract where the motor deficit localized (38 of 38 [100%]) than on the contralateral side (15 of 38 [39%]) (p < 0.0001).ConclusionsIn patients with MS with unilateral motor progression, the motor deficit may be attributable to a single critical corticospinal tract lesion.
UR - http://www.scopus.com/inward/record.url?scp=85071354372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071354372&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000007944
DO - 10.1212/WNL.0000000000007944
M3 - Article
C2 - 31289142
AN - SCOPUS:85071354372
SN - 0028-3878
VL - 93
SP - E628-E634
JO - Neurology
JF - Neurology
IS - 7
ER -